Dr. Reddy's Laboratories posts Q2 FY27 revenue decline and profit slump
Dr. Reddy's Laboratories reported fiscal second‑quarter 2027 results on 23 Oct 2026. Revenue fell year‑over‑year, with Indian‑rupee figures showing ₹8,671 crores (down 1.5%) and U.S.‑dollar figures showing $903.9 million (down 8.8%). Profit after tax dropped to ₹925 crores (≈$97 million) and operating profit fell to $132.2 million, while diluted earnings per share fell to $0.12. The company highlighted double‑digit growth in its base business and announced several product launches and partnerships.
Why it matters
The sharp decline in revenue and profitability reduces earnings per share and may pressure the stock, which fell 2.69% in morning trading. The company’s cash surplus of ₹2,502 crores remains a buffer, but lower cash generation signals weaker operating cash flow.
Key facts
- 1Revenue was ₹8,671 crores, down 1.5% YoY. investing.com
- 2Revenue was $903.9 million, down 8.8% YoY. quiverquant.com
- 3Profit after tax was ₹925 crores. investing.com
- 4Operating profit was $132.2 million, down 71.6% YoY. quiverquant.com
- 5Net income was $96.4 million, down 40.4% YoY. quiverquant.com
- 6Diluted EPS fell to $0.12, down 33.3% YoY. quiverquant.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.